Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TCF4 | P15884 | 1/20 | 0.62 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SNCA | P37840 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15056080 | 0.88 | ALDH1A1 (0.55) | MCL1SMN1; SMN2HPGDALDH1A1KDM4E | |
| SCHEMBL15055658 | 0.87 | ALDH1A1 (0.67) | MAPTMEN1KMT2AFFAR4MCL1 | |
| SCHEMBL15056016 | 0.87 | SMN1; SMN2 (0.70) | MEN1KMT2ASMN1; SMN2HPGDCYP2C9 | |
| SCHEMBL1130086 | 0.86 | MCL1 (0.68) | MAPTMEN1KMT2AMCL1SNCA | |
| SCHEMBL15055763 | 0.86 | ALDH1A1 (0.57) | TCF4CTNNB1MAPTMEN1KMT2A | |
| SCHEMBL15056053 | 0.86 | PTPN5 (0.66) | MAPTMEN1KMT2AMCL1SMN1; SMN2 | |
| SCHEMBL15055884 | 0.86 | MCL1 (0.61) | TCF4CTNNB1MAPTMEN1KMT2A | |
| SCHEMBL15055519 | 0.85 | MCL1 (0.64) | TCF4CTNNB1MAPTMEN1KMT2A | |
| SCHEMBL15055896 | 0.85 | MEN1 (0.54) | MEN1KMT2AMCL1SMN1; SMN2GAA | |
| SCHEMBL15055358 | 0.84 | ALDH1A1 (0.57) | MAPTMEN1KMT2AFFAR4MCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | claimed |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2016-08-04 | — | — | US | claimed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | claimed |
| EP-2794009-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | Kancera AB (SE) | 2014-10-29 | — | — | EP | claimed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | claimed |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2018-06-19 | — | — | US | disclosed |
| EP-2794009-B1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2017-08-30 | — | — | EP | disclosed |
| US-9718809-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | KANCERA AB (SE) | 2017-08-01 | — | — | US | disclosed |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2016-08-04 | — | — | US | disclosed |
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2015-01-22 | — | — | US | disclosed |
| EP-2794009-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | Kancera AB (SE) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093095-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | KANCERA AB (SE) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025068-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | TCF4 3628/4885CTNNB1 1702/4885MAPT 2479/4885 |
| US-20160221938-A1 | BISARYLSULFONAMIDES USEFUL IN THE TREATMENT OF INFLAMMATION AND CANCER | NFKBIA, IL6, LITAF | TCF4 3739/4885CTNNB1 1856/4885MAPT 2736/4885 |
| US-10000449-B2 | Bisarylsulfonamides useful in the treatment of inflammation and cancer | NFKBIA, IL6, LITAF | TCF4 3739/4885CTNNB1 1856/4885MAPT 2736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.